Equity · Healthcare
TNYA
NASDAQTenaya Therapeutics (TNYA)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 159.0M USD
- EPS, diluted, year to Dec 2025
- −0.59 USD
- 52-week range
- 0.5527 USD – 2.09 USD
- Avg volume
- 153.5K
as of Aug 26, 2026
Have Tenaya Therapeutics (TNYA) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Tenaya Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 17 Nov 2025, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 17 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | Ali FarazChief Executive Officer | Sell | 3,499 | 1K USD |
| 17 Nov 2026 | Tingley WhittemoreChief Medical Officer | Sell | 3,223 | 1K USD |
| Sold | 2 open-market sales | 6,722 | $2K |
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Sep 2026 | Ali FarazChief Executive Officer | Award | 122,000 | |
| 10 Sep 2026 | Tingley WhittemoreChief Medical Officer | Award | 49,000 |
Which funds hold Tenaya Therapeutics (TNYA)?
5 of the 45 institutional funds we track reported a Tenaya Therapeutics position for the quarter ended 30 Sep 2026 — a combined 12.8M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Added | 10,244,875 | 6.2M USD | +59.3% |
| Citadel Advisors | Held (±25%) | 4,505,083 | 2.7M USD | −1.4% |
| Renaissance Technologies | Trimmed | 2,960,200 | 1.8M USD | −30.9% |
| Marshall Wace | Trimmed | 2,568,551 | 1.5M USD | −26.7% |
| Two Sigma Investments | Added | 1,002,817 | 605K USD | +163.4% |
| Point72 Asset Management | Exited |
What has been filed or recorded for Tenaya Therapeutics (TNYA)?
The filings we hold for Tenaya Therapeutics, newest first: 9 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 28 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 386 shares | 154 USD notional · <0.001% of shares out |
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 54,805 shares | 22K USD notional · 0.024% of shares out |
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 407 shares | 159 USD notional · <0.001% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 34,948 shares | 14K USD notional · 0.015% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 32,402 shares | 13K USD notional · 0.014% of shares out |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 28,800 shares | 11K USD notional · 0.013% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 53,017 shares | 20K USD notional · 0.023% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 125 shares | 71 USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,613 shares | 3K USD notional · 0.002% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.08 USD | Revenue $2M |
| 30 Sep 2026 | Financials | Total assets | 76.7M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 54.5M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.20 USD | Revenue $1M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.09 USD | Revenue $0M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.59 USD | |
| 31 Dec 2025 | Financials | Net income | −90.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.59 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.12 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.14 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.24 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.31 USD |
What do people ask about Tenaya Therapeutics (TNYA)?
What did Tenaya Therapeutics shares close at?0.6977
Tenaya Therapeutics closed at 0.6977 USD on 26 Aug 2026, down 1.15% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Tenaya Therapeutics’ market cap?159.0M
Tenaya Therapeutics is worth 159.0M USD by market value as of 26 Aug 2026, which is the share price times the shares on issue from its SEC filings.
Have Tenaya Therapeutics insiders bought or sold shares recently?2 sales
In the 90 days to 22 Nov 2026, Tenaya Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 17 Nov 2025, show no open-market purchase. A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Tenaya Therapeutics?5 of 45
5 of the 45 funds we track reported a Tenaya Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Citadel Advisors and Renaissance Technologies. See Funds
When did Tenaya Therapeutics last report earnings?−0.08
Tenaya Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.08 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words